Vice President, General Therapeutics Marketing, Sanofi-Aventis US
The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system. This begs the question of how we can meet the future needs of the healthcare system—and how we can pay for it. We need to engage in the disruptive innovation that is critical to meet the evolving needs of the elderly.
In 10 years, I think the traditional pharma/bio model will have evolved from a treatment approach to one of providing total healthcare solutions, including preventative and diagnostic products, treatments, and maintenance support for patients. Thus, there will be a shift from our current target audiences (typically physicians) to the entire continuum of healthcare treaters.I see my current roles as a senior-level businesswoman at Sanofi-Aventis and the president of the Healthcare Businesswomen's Association (HBA) as my great accomplishments. My role at HBA allows me to lead a board of directors that oversees numerous complex and successful events, such as WOTY (Woman of the Year), the Annual Leadership Conference, and other educational offerings provided by 14 chapters worldwide. During my presidential tenure at HBA, we are shoring up the strategic growth platform that will sustain the long-term viability of the organization. It's a wonderful way to give back!